Pre-made Ibritumomab Tiuxetan benchmark antibody (Radiolabelled antibody, anti-MS4A1/CD20 therapeutic antibody, Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-made Ibritumomab Tiuxetan benchmark antibody (Radiolabelled antibody, anti-MS4A1/CD20 therapeutic antibody, Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Ibritumomab tiuxetan (pronounced /ɪbrɪtuːmoʊmæb taɪʌksɛtæn/[1]), sold under the trade name Zevalin, is a monoclonal antibody radioimmunotherapy treatment for non-Hodgkin's lymphoma. The drug uses the monoclonal mouse IgG1 antibody ibritumomab in conjunction with the chelator tiuxetan, to which a radioactive isotope (either yttrium-9 or indium-111) is added. Tiuxetan is a modified version of DTPA whose carbon backbone contains an isothiocyanatobenzyl and a methyl group.[2][3]

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-859-1mg	1mg	3090
GMP-Bios-INN-859-10mg	10mg	Inquiry
GMP-Bios-INN-859-100mg	100mg	Inquiry
GMP-Bios-INN-859-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Ibritumomab Tiuxetan Biosimilar, Radiolabelled Antibody, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody
INN Name	Ibritumomab Tiuxetan
Target	MS4A1/CD20
Format	Radiolabelled antibody
Derivation	Mus musculus
Species Reactivity	human
CH1 Isotype	IgG1 - kappa
VD LC	IgG1 - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Biogen, Inc. (Cambridge MA USA) / Schering AG (Berlin Germany) / Spectrum Pharmaceuticals, Inc. (Irvine CA USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0